Skip to main content
Springer logoLink to Springer
. 2021 Jun 10;17(1):123–134. doi: 10.1007/s11739-021-02780-2

Validation of the Italian HeartQoL: a short health-related quality of life questionnaire for patients with ischemic heart disease

Francesco Fattirolli 1,, Alessia Argirò 1, Maria Elisabetta Angelino 2, Gianluigi Balestroni 3, Francesco Giallauria 4, Daniela Miani 5, Carlo Vigorito 4, Lucrezia Piccioli 1,2,3,4, Franco Tarro Genta 6, Stefan Höfer 7, Niccolò Marchionni 1, Neil Oldridge 8
PMCID: PMC8841307  PMID: 34110564

Abstract

The psychometric properties of the core disease-specific 14-item Italian HeartQoL health-related quality of life questionnaire have been evaluated in this study. The Italian version of the HeartQoL, the MacNew questionnaire, and the Hospital Anxiety and Depression Scale were completed by 472 patients (angina, N = 183; myocardial infarction, N = 167; or ischemic heart failure, N = 122) who were recruited in five Italian centers (Florence, Veruno, Turin, Udine, and Naples) between 2015 and 2017. Patients with myocardial infarction reported significantly higher HeartQoL scores than patients with angina or ischemic heart failure. Floor and ceiling effects were always minor on the HeartQoL global scale and physical subscale with moderate ceiling effects on the emotional subscale in the total group and in patients with myocardial infarction. The bifactorial structure of the original HeartQoL questionnaire was confirmed with strong physical, emotional, and global scale H coefficients (> 0.50). The HeartQoL scales demonstrated optimal internal consistency (Cronbach’s alpha > 0.84). Convergent and divergent validity were confirmed. Discriminative validity was not confirmed for age, largely confirmed for sex, and fully confirmed for anxiety, depression, and distress. The Italian HeartQoL questionnaire demonstrated adequate key psychometric attributes of internal consistency reliability and validity in Italian-speaking patients with ischemic heart disease.

Keywords: Health-related quality of life, Italian HeartQoL questionnaire, Angina pectoris, Myocardial infarction, Ischemic heart failure, Validation

Background

Critical steps in improving the quality of health care include evidence-based, patient-centered, and systems-oriented care [1]. Incorporating this approach has changed medicine in all areas, from everyday practice, where shared decision making has become essential and recommended by guidelines [2] to clinical trials where patients are involved in Steering Committees [3]. Major treatment goals for patients with cardiovascular disease include a focus on health status which includes symptom burden, functional limitations, and health-related quality of life (HRQL) [4, 5]. Health status typically is evaluated with patient-reported outcome questionnaires through which patients may express feelings about their health condition without adulteration or interpretation by clinicians [6].

Both generic and disease-specific patient-reported outcome questionnaires can be used to evaluate and compare the health status. Generic instruments, such as the SF-36 Health Survey (SF-36) [7, 8], are designed for use in healthy populations, different disease populations as well as between healthy populations and populations with various diseases. On the other hand, disease-specific instruments, such as the Seattle Angina Questionnaire [9] and the Minnesota Living with Heart Failure questionnaire [10] provide more relevant disease-specific information than generic instruments. However, there is a need for core disease-specific questionnaires which permit between-diagnosis comparisons within a given disease with a single questionnaire, for example, the MacNew [11] and, more recently, the HeartQoL [12, 13] in patients with ischemic heart disease (IHD).

The HeartQoL questionnaire was developed with the objective of assessing HRQL using a single instrument in patients with angina pectoris (AP), myocardial infarction (MI), or ischemic heart failure (IHF). The HeartQoL Project was conducted between 2002 and 2011 in European and English speaking regions in two phases: first, a cross-sectional survey to identify items for questionnaire inclusion on the basis of three previously validated instruments [12], the Seattle Angina Questionnaire, [9] the MacNew Heart Disease Health-related Quality of Life Questionnaire (MacNew) [11], and the Minnesota Living with Heart Failure questionnaire [10], and a second phase to evaluate the HeartQoL questionnaire’s psychometric properties [13]. The result was a bifactorial, 14-item questionnaire that was reliable, valid, and responsive in patients with AP, MI, or IHF [13]. These results have been recently confirmed in German [14] and Chinese [15] and also in other clinical contexts, such as atrial fibrillation [16], implantable cardioverter defibrillator recipients [17], and valve surgery [18].

To optimize their use as both research and clinical tools, patient-reported HRQL questionnaires need to meet basic attributes such as reliability and validity [19]. Reliability is considered the degree to which a questionnaire is free from random error with internal consistency reliability the intercorrelations of items at one point in time. Validity is the degree to which the instrument really measures what it purports to measure and includes convergent validity (the degree to which two theoretically related measures are in fact related), divergent validity (the degree to which two dissimilar measures can be differentiated) and discriminative validity (does the questionnaire adequately discriminate between groups that should or should not differ). The purpose of this study was to examine the factor structure, reliability, convergent, divergent, and discriminative validity of the Italian version of the HeartQoL questionnaire in patients with AP, MI, or IHF.

Methods

Patients

Patients diagnosed with IHD [n = 472] were recruited at five sites in Italy (Florence, Veruno, Turin, Udine, and Naples) from 2015 to 2017. The eligibility criteria were extracted from the original cross-sectional survey phase of the HeartQoL Project [12] and included:

(a) currently being treated for AP [20] with an objective measure of IHD (e.g., previous MI, exercise testing, echocardiogram, nuclear cardiac imaging, or coronary angiography); or

(b) had experienced a documented MI between one to six months previously; or

(c) currently being treated for IHF with evidence of left ventricular dysfunction (ejection fraction ≤ 40% by invasive or non-invasive testing) and an objective measure of IHD (e.g., exercise testing, echocardiogram, nuclear cardiac imaging, or coronary angiography).

The patients were ≥ 18 years, able to complete the self-administered battery of HRQL questionnaires in Italian, without hospitalization in the last 6 weeks, without serious psychiatric disorder as well as no current substance abuse as identified by the referring physician. The Ethics Committee in each study site approved the project and informed consent was obtained from all patients.

Patient-reported questionnaires

Sociodemographic and clinical variables

Demographic characteristics of age, sex, family status, education, employment, and cardiovascular risk factors (diabetes, hypercholesterolemia, hypertension, physical inactivity, and smoking) were self-reported by patients.

HeartQoL

The Italian version of the disease-specific HeartQoL was used in the HeartQoL Project [12] and in this study to measure HRQL. The HeartQoL is a bi-dimensional instrument with a 10-item physical subscale and a 4-item emotional subscale that, when combined, provides the 14-item global scale [12]. The responders answer the question of how much they are bothered by each of the 14 HeartQoL questionnaire items on a 4-point scale ranging from “bothered a lot” (= 0) to “not bothered” (= 3) with higher scores indicating better HRQL. Both the global scale and the subscales were calculated as the mean of the scored items.

Hospital anxiety and depression scale (HADS)

The HADS is a 14-item self-assessment questionnaire including an anxiety and a depression subscale that together generate a common score for general distress; the Italian version was used in this study [21, 22]. The items are answered on a scale ranging from 0 to 3 with higher scores representing higher levels of anxiety or depression. A subscale cutoff score ≥ 8 identifies patients with symptoms of depression or anxiety [22] and a global cutoff score ≥ 12 indicates “general” distress.

MacNew

The MacNew Questionnaire is designed to assess patient’s feelings about how IHD affects daily functioning [11]. It contains 27 items with a global HRQL score and physical limitation, emotional and social function subscales, scored from 1 (low HRQL) to 7 (high HRQL) [23, 24]. Using forward–backward translation, the MacNew questionnaire had been translated into Italian and validated as part of the HeartQoL Project [25].

Statistical analyses

Means and standard deviation (SD) are reported for continuous variables and frequencies for categorical variables. Categorical sociodemographic and clinical variables were analyzed with Pearson’s Chi-square test while continuous variables and scale means were examined with analyses of co-variance (ANCOVA) with post hoc Bonferroni correction adjusting for age, sex, risk factors, and disease severity within diagnosis. A two-sided p value of < 0.05 was applied for statistical significance. The data were analyzed using IBM SPSS Statistics 24 and STATA 14.

The evaluation of the psychometric properties of the Italian HeartQoL followed criteria recommended by the Scientific Advisory Committee [19]. Floor and ceiling effects of the HeartQoL are considered moderate when > 15% patients report the lowest score (= 0; floor) or the highest score (= 3; ceiling) [26]. A confirmatory Mokken scale analysis, using Loevinger’s coefficient H of ≥ 0.50 considered a “strong,” 0.49–0.40 a “moderate,” and 0.39–0.30 a “weak” scale [27], was performed to assess whether the established two-factor structure of HeartQoL [12] could be confirmed in the Italian HeartQoL. Internal consistency reliability was determined using Cronbach’s alpha with values of ≥ 0.70 acceptable for group and ≥ 0.90 for individual comparisons [28]. The strength of the correlations between HeartQoL and related (convergent) as well as unrelated (divergent) constructs was assessed with Pearson coefficients (r < 0.10 = no correlation, r = 0.10–0.29 = low correlation, r = 0.30–0.49 = moderate correlation, r ≥ 0.50 = high correlation) with Steiger’s test used for differences in correlations [29]. Discriminative validity was tested for using the “known-groups” approach [26] with paired t tests used to compare HeartQoL scores with two-level variables and one-way ANOVA used to compare three-level variables. The following discriminative validity hypotheses test whether significantly higher HeartQoL scores are reported:

  1. by younger than by middle-age or older patients,

  2. by male patients than by female patients,

  3. by patients with MI than by patients with either AP or IHF,

  4. by patients reporting higher MacNew HRQL scores (top 33% of actual scores) than by lower scores (bottom 33% of actual scores),

  5. by patients without HADS anxiety (score < 8) than by patients with HADS anxiety (score ≥ 8)

  6. by patients without HADS depression (score < 8) than by patients with HADS depression (score ≥ 8) and

  7. by patients without HADS general distress (score < 12) than by patients with HADS general distress (score ≥ 12).

Results

Patient characteristics (Table 1)

Table 1.

Patient characteristics: sociodemographic, risk factor, and intervention variables in patients with angina (AP), myocardial infarction (MI), or ischemic heart failure (IHF)

Total cohort
(N = 472)
AP
(N = 183; 38.8%)
MI
(N = 167; 35.4%)
IHF
(N = 122; 25.8%)
P value
Age
 Years ± SD 65.4 ± 12.5 67.5 ± 10.9 63.1 ± 11.4 65.3 ± 14.5 0.004
Gender
 Female 120 (25.4%) 52 (28.4%) 36 (21.5%) 32 (26.2%) ns
 Male 352 (74.6%) 131 (72.6%) 131 (78.4%) 90 (73.8%)
Marital Status (N = 463)
 Single 67 (14.5%) 26 (14.6%) 22 (13.3%) 19 (15.8%) ns
 Married/partnership 355 (76.7%) 134 (75.3%) 129 (78.2%) 92 (76.7%)
 Other 41 (8.8%) 18 (10.1%) 14 (8.5%) 9 (7.5%)
Education (N = 460)
 < High school 239 (51.9%) 96 (53.3%) 82 (50%) 61 (52.6%) ns
 = High school 172 (37.4%) 68 (37.8%) 67 (40.9%) 37 (31.9%)
 > High school 49 (10.7%) 16 (8.9%) 15 (9.2%) 18 (15.5%)
Employment (N = 461)
 Unemployed 45 (9.8%) 14 (7.82%) 16 (9.8%) 15 (12.6%) ns
 Retired 253 (54.9%) 113 (63.1%) 75 (46.0%) 65 (54.6%) ns
 Employed 163 (35.3%) 52 (29.1%) 72 (44.2%) 39 (32.8%) 0.017
Risk factors
 BMI 27.0 ± 4.7 27.2 ± 4.4 26.9 ± 4.4 26.9 ± 5.5 ns
 Diabetes § 113 (24.0%) 49 (26.9%) 33 (19.8%) 31 (25.6%) ns
 Hypercholesterolemia § 229 (50.6%) 88 (50.6%) 95 (59.4%) 46 (38.7%) 0.003
 Hypertension § 249 (53.8%) 108 (60%) 91 (55.8%) 50 (41.7%) 0.006
 Physical inactivity # 213 (47.1%) 84 (48.35) 67 (41.4%) 62 (53.4%) ns
 Smoking 79 (17.2%) 28 (16%) 30 (18.1%) 21 (17.8%) ns
Intervention
 PTCA 166 (35.5%) 49 (27.1%) 101 (60.5%) 16 (13.3%) 0.001
 CABG 60 (12.8%) 32 (17.6%) 15 (9%) 13 (10.7%) 0.041
 Valve surgery 19 (4.0%) 4 (2.2%) 4 (2.4%) 11 (9.1%) 0.005

N number of patients (sub-group N does not always = 472 due to missing data)

p value between diagnosis using Chi-square tests with categorical variables and ANCOVA with continuous variables (post hoc Bonferroni correction and scores adjusted for age, sex, and risk factors);

BMI body mass index, § Physician reported, # Patient-reported active on < 3 occasions per week, PTCA percutaneous transluminal coronary angioplasty, CABG coronary artery bypass grafting

A total of 472 patients with documented AP (N = 183, 38.8%), previous MI (N = 167, 35.4%) or IHF (N = 122, 25.8%) were eligible for the validation of the Italian HeartQoL Questionnaire. The mean age of the total cohort was 65.4 ± 12.5 years. The majority of patients (74.6%) were male, most were married (76.7%), 52% had less than high school education, and 54.9% were retired. Hypertension was the most prevalent risk factor (53.8%) followed by hypercholesterolemia (50.6%) and physical inactivity (47.1%) with differences in risk factors by diagnosis detailed in Table 1.

Patient-reported questionnaire score distributions (Table 2)

Table 2.

Scores (mean ± standard deviation) on HeartQoL, Hospital Anxiety, and Depression Scale (HADS) and MacNew and percentage HADS anxious, depressed, and distressed in the total cohort and in patients with angina (AP), myocardial infarction (MI), or ischemic heart failure (IHF)

Total cohort
(N = 472)
AP
(N = 183; 38.8%)
MI
(N = 167; 35.4%)
IHF
(N = 122; 25.8%)
P-value
HeartQoL
 Global scale 2.0 ± 0.7 1.9 ± 0.7 2.3 ± 0.6 1.7 ± 0.8  < 0.001a, b
 Physical subscale 1.9 ± 0.8 1.9 ± 0.8 2.2 ± 0.7 1.6 ± 0.9  < 0.001 a, b
 Emotional subscale 2.2 ± 0.8 2.1 ± 0.8 2.3 ± 0.7 2.0 ± 0.8  < 0.002a, b
MacNew
 Global scale 5.2 ± 1.1 5.1 ± 1.0 5.5 ± 1.0 4.9 ± 1.1  < 0.001a, b
 Physical subscale 5.2 ± 1.2 5.1 ± 1.2 5.6 ± 1.0 4.9 ± 1.2  < 0.001a, b
 Emotional subscale 5.1 ± 1.3 5.0 ± 1.1 5.3 ± 1.1 4.9 ± 1.2  < 0.002a, b
HADS
 Anxiety score 5.2 ± 3.9 5.5 ± 4.0 5.0 ± 4.1 5.2 ± 3.8 ns
 Anxious (score, ≥ 8) 130 (27.1%) 47 (25.7%) 46 (27.5%) 35 (28.7%) ns
 Depression score 5.5 ± 4.2 5.7 ± 4.0 4.7 ± 4.2 6.3 ± 4.4  < 0.001a
 Depressed (score, ≥ 8) 132 (27.9%) 57 (30.4%) 37 (22.2%) 39 (32.2%) ns
 General distress score 10.7 ± 7.4 11.2 ± 7.2 9,7 ± 7.6 11.5 ± 7.5 ns
 Distressed (score, ≥ 12) 194 (41.1%) 79 (40.7%) 58 (29.9%) 57 (29.4%) ns

p value between diagnosis using ANCOVA (post hoc Bonferroni correction and scores adjusted for age, sex, and risk factors)

aMI vs. HF

bMI vs. AP

HeartQoL Mean HeartQoL HRQL scores for the total cohort were 2.0 ± 0.7 on the global scale, 1.9 ± 0.8 on the physical subscale and 2.2 ± 0.8 on the emotional subscale with ANCOVA results demonstrating significantly higher global scale and both physical and emotional score differences in patients with MI than patients with either AP or IHF.

MacNew The mean MacNew global HRQL score was 5.2 ± 1.1, the mean physical subscale score was 5.2 ± 1.2 and the mean emotional subscale score was 5.1 ± 1.3 in the total group. Using ANCOVA, there were significant score differences between patients with MI and those with either AP or IHF on the global scale and both physical and emotional subscales with patients with MI reporting higher HRQL than patients with either AP or IHF.

Hospital Anxiety and Depression Scale For the total cohort, the mean HADS anxiety score was 5.2 ± 3.9 with anxiety scores ≥ 8 reported by 27.1% of the total cohort. The mean HADS depression score in the total cohort was 5.5 ± 4.2 with depression scores ≥ 8 reported by 27.9% of the total cohort. The mean HADS general distress score in the total cohort was 10.7 ± 7.4 with general distress scores ≥ 12 reported by 41.1% of the total cohort. Although patients with IHF reported significantly higher depression scores than patients with MI, the anxiety scores, the general distress scores and the proportions of patients with HADS anxiety or depression scores ≥ 8 or general distress scores ≥ 12 were not significantly different by diagnosis.

Mokken scale factor structure (Table 3)

Table 3.

Mokken scale analysis in in the total cohort for the HeartQoL items with Loevinger’s Hi (item) and H (scale) coefficients (strong, ≥ 0.50, moderate, 0.49 to 0.40)

Item Global Hi
(N = 433)
Physical Hi
(N = 460)
Emotional Hi
(N = 462)
1. Walk indoors on level ground? 0.57 0.64
2. Garden. vacuum. or carry groceries? 0.62 0.70
3. Climb a hill or a flight of stairs without stopping? 0.62 0.69
4. Walk more than 100 yards at a brisk pace? 0.62 0.70
5. Lift or move heavy objects? 0.62 0.68
6. Feeling short of breath? 0.56 0.61
7. Being physically restricted? 0.66 0.69
8. Feeling tired. fatigued. low on energy? 0.65 0.67
9. Not feeling relaxed and free of tension? 0.49 0.69
10. Feeling depressed? 0.47 0.70
11. Being frustrated? 0.55 0.63
12. Being worried? 0.53 0.72
13. Being limited in doing sports or exercise? 0.60 0.63
14. Working around the house or yard? 0.61 0.67
HeartQoL H 0.59 0.67 0.68

With Mokken analysis, the HeartQoL H coefficients were rated as “strong” on the global scale (0.59) and on both the physical (0.67) and the emotional (0.68) subscales confirming the original HeartQoL two-factor structure. Of the HeartQoL Hi coefficients, 85.8% of the items on the global scale (12 of 14 items; Hi range, 0.47–0.66) and 100% of the items on both the physical subscale (10 items; Hi range, 0.61 to 0.70) and the emotional subscale (4 items; Hi range, 0.63 to 0.72) were rated as “strong”.

HeartQoL floor and ceiling effects (Table 4)

Table 4.

Italian HeartQoL floor and ceiling effects and internal consistency reliability (Cronbach’s alpha) in the total cohort and in patients with angina (AP), myocardial infarction (MI), or ischemic heart failure (IHF)

HeartQoL Total cohort
(N = 472)
AP
(N = 183; 38.8%)
MI
(N = 167; 35.4%)
IHF
(N = 122; 25.8%)
Global scale
 Floor effect 0.4% 1.0% 0.6% 1.0%
 Ceiling effect 4.7% 3.8% 7% 2.50%
 Cronbach’s alpha 0.94 0.94 0.93 0.94
Physical subscale
 Floor effect 0.6% 1.0% 1.2% 1.0%
 Ceiling effect 7.4% 6.0% 10.8% 4.90%
 Cronbach’s alpha 0.94 0.93 0.92 0.95
Emotional subscale
 Floor effect 1.7% 1.0% 0.6% 1.6%
 Ceiling effect 16.5% 14.8% 22.2% 11.5%
 Cronbach’s alpha 0.87 0.88 0.86 0.84

N number of patients;

Floor effect > 15% reporting poorest HRQL

Ceiling effect > 15% reporting highest HRQL

Floor effects on the HeartQoL global scale and both subscales were always ≤ 1.7% in the total group and in each diagnosis.

Ceiling effects on the HeartQoL global scale and the physical subscale were always ≤ 10.8% in the total group and in each diagnosis with moderate ceiling effects on the emotional subscale as high as 16.5% in the total group and 22.2% in patients with MI.

Psychometric properties of the HeartQoL (Tables  2, 4, 5, & 6)

Reliability (Table 4) Internal consistency reliability was confirmed with Cronbach’s alpha ranging from 0.87 to 0.94 in the total cohort, from 0.88 to 0.94 in patients with AP, from 0.86 to 0.93 in patients with MI and from 0.84 to 0.95 in patients with IHF.

Convergent validity (Table 5) Convergent validity was confirmed in the total cohort and each diagnosis with correlations between the HeartQoL and MacNew physical subscales ranging from 0.71 to 0.75 and from 0.79 to 0.84 between the HeartQoL and MacNew emotional subscales. Correlations between dissimilar scales of both instruments were significantly lower according to Steiger’s test for comparing Pearson correlations confirming divergent validity.

Table 5.

Convergent validity of the Italian HeartQoL subscales with the MacNew subscales in the total cohort and in patients with angina pectoris (AP), myocardial infarction (MI), or ischemic heart failure (IHF)

HeartQoL
Physical subscale Emotional subscale p-value#
Total cohort (N = 472)
 MacNew Physical 0.75 0.70 0.05
 MacNew Emotional 0.57 0.81  < 0.001
 p value#  < 0.001  < 0.001
AP (N = 183)
 MacNew Physical 0.74 0.71 0.427
 MacNew Emotional 0.59 0.81  < 0.001
 p value#  < 0.01  < 0.05
MI (N = 167)
 MacNew Physical 0.71 0.72 0.094
 MacNew Emotional 0.57 0.84  < 0.001
 p value#  < 0.05  < 0.01
IHF (N = 122)
 MacNew Physical 0.73 0.64 0.274
 MacNew Emotional 0.51 0.79  < 0.001
 p value#  < 0.01  < 0.01

N number of patients;

Strong Pearson’s correlation coefficients between similar HeartQoL and MacNew subscales are bolded; all correlation coefficients, p < 0.01

#Steiger’s test for comparing Pearson’s correlations

Discriminative validity (Tables 2, 6) Discriminative validity for the HeartQoL was fully confirmed for diagnosis, MacNew global HRQL scores, HADS anxiety, depression, and general distress, largely confirmed for sex, and essentially not confirmed for age.

Table 6.

Discriminative validity of the Italian HeartQoL in the total cohort and in patients with angina pectoris (AP), myocardial infarction (MI), or ischemic heart failure (IHF)

HeartQoL Global scale Physical subscale Emotional subscale
Total cohort (N = 472)
Age
 Young (N = 148) 2.08 [1.96–2.20] 2.1 [1.92–2.18] 2.17 [2.04–2.30]
 Middle-age (N = 162) 2.01 [1.90–2.13] 1.95 [1.83–2.08] 2.16 [2.04–2.28]
 Elderly (N = 151) 1.89 [1.78–2.01] 1.78 [1.65–1.91] 2.18 [2.06–2.30]
p value ns  < .05; # ns
Sex
 Female (N = 120) 2.09 [2.01–2.17] 2.02 [1.94–2.11] 2.25 [2.17–2.32]
 Male (N = 351) 1.71 [1.58–1.85] 1.63 [1.49–1.77] 1.92 [1.78–2.09]
 p value  < .001  < .001  < .001
MacNew—global score
 Top tertile (N = 154) 2.60 [2.54–2.63] 2.52 [2.45–2.60] 2.77 [2.73–2.81]
 Bottom tertile (N = 157) 1.29 [1.20–1.39] 1.25 [1.14–1.36] 1.40 [1.29–1.52]
 p value  < .001  < .001  < .001
HADS*
 Anxious (N = 128) 1.40 [1.28–1.53] 1.43 [1.30–1.57] 1.33 [1.20–1.46]
 Not anxious (N = 343) 2.21 [2.15–2.28] 2.11 [2.03–2.19] 2.47 [2.41–2.53]
 p value  < .001  < .001  < .001
 Depressed (N = 131) 1.37 [1.25–1.49] 1.36 [1.22–1.49] 1.41 [1.27–1.54]
 Not depressed (N = 337) 2.24 [2.18–2.31] 2.15 [2.07–2.23] 2.46 [2.41–2.52]
 p value  < .001  < .001  < .001
 Stressed (N = 194) 1.48 [1.39–1.58] 1.46 [1.35–2.58] 1.53 [1.43–1.64]
 Not stressed (N = 227) 2.35 [2.29–2.41] 2.25 [2.17–2.34] 2.60 [2.56–2.65]
 p value  < .001  < .001  < .001
AP (N = 183)
Age
 Young (N = 41) 1.95 [1.71–2.20] 1.93 [1.67–2.20] 2.02 [1.73–2.30]
 Middle age (N = 64) 1.97 [1.79–2.15] 1.92 [1.72–2.12] 2.10 [1.92–2.29]
 Elderly (N = 74) 1.90 [1.73–2.07] 1.79 [1.60–1.97] 2.17 [1.99–2.35]
 p value ns ns ns
Sex
 Female (N = 52) 2.00 [1.88–2.13] 1.93 [1.79–2.07] 2.17 [2.04–2.31]
 Male (N = 130) 1.74 [1.53–1.95] 1.68 [1.46–1.90] 1.90 [1.67–2.12]
 p value  < .05 ns  < .05
MacNew—global
 Top tertile (N = 70) 2.60 [2.50–2.69] 2.52 [2.39–2.65] 2.78 [2.70–2.85]
 Bottom tertile (N = 51) 1.33 [1.17–1.49] 1.30 [1.12–1.48] 1.42 [1.23–1.61]
 p value  < .001  < .001  < .001
HADS*
 Anxious (N = 47) 1.32 [1.10–1.55] 1.38 [1.13–1.62] 1.20 [0.96–1.43]
 Not anxious (N = 135) 2.14 [2.03–2.24] 2.03 [1.91–2.15] 2.41 [2.32–2.49]
 p value  < .001  < .001  < .001
 Depressed (N = 55) 1.35 [1.16–1.53] 1.33 [1.13–1.53] 1.40 [1.18–1.61]
 Not depressed (N = 125) 2.19 [2.08–2.30] 2.10 [1.98–2.23] 2.41 [2.31–2.51]
 p value  < .001  < .001  < .001
 Stressed (N = 79) 1.45 [1.30–1.61] 1.44 [1.27–1.62] 1.48 [1.31–1.65]
 Not stressed (N = 103) 2.29 [2.19–2.40] 2.18 [2.05–2.31] 2.57 [2.48–2.65]
 p value  < .001  < .001  < .001
MI (N = 167)
Age
 Young (N = 66) 2.31 [2.14–2.47] 2.29 [2.12–2.47] 2.34 [2.16–2.51]
 Middle age (N = 59) 2.29 [2.14–2.44] 2.26 [2.10–2.42] 2.36 [2.18–2.53]
 Elderly (N = 38) 2.13 [1.92–2.34] 2.06 [1.82–2.29] 2.31 [2.08–2.54]
 p value ns ns ns
Sex
 Female (N = 36) 2.33 [2.23–2.43] 2.31 [2.21–2.42] 2.36 [2.24–2.48]
 Male (N = 131) 2.00 [1.77–2.22] 1.91 [1.66–2.16] 2.22 [1.98–2.45]
 p value  < .005  < .001 ns
MacNew—global
 Top tertile (N = 77) 2.63 [2.56–2.70] 2.57 [2.47–2.67] 2.77 [2.71–2.84]
 Bottom tertile (N = 34) 1.40 [1.22–1.58] 1.44 [1.23–1.64] 1.32 [1.08–1.55]
 p value  < .001  < .001  < .001
HADS*
 Anxious (N = 46) 1.71 [1.52–1.89] 1.76 [1.56–1.96] 1.57 [1.36–1.78]
 Not anxious (N = 121) 2.47 [2.38–2.55] 2.40 [2.30–2.51] 2.62 [2.54–2.70]
 p value  < .001  < .001  < .001
 Depressed (N = 37) 1.67 [1.44–1.90] 1.72 [1.47–1.96] 1.53 [1.25–1.81]
 Not depressed (N = 130) 2.43 [2.34–2.51] 2.37 [2.27–2.47] 2.56 [2.48–2.64]
 p value  < .001  < .05  < .001
 Stressed (N = 58) 1.77 [1.60–1.93] 1.79 [1.61–1.98] 1.70 [1.50–1.90]
 Not stressed (N = 109) 2.52 [2.44–2.60] 2.46 [2.36–2.56] 2.67 [2.60–2.73]
 p value  < .001  < .001  < .001
IHF (N = 122)
Age
 Young (N = 41) 1.85 [1.62–2.09] 1.77 [1.50–2.05] 2.04 [1.79–2.29]
 Middle age (N = 39) 1.66 [1.40–1.92] 1.54 [1.25–1.82] 1.96 [1.68–2.25]
 Elderly (N = 39) 1.66 [1.40–1.91] 1.49 [1.19–1.79] 2.08 [1.84–2.31]
 p value ns ns ns
Sex
 Female (N = 32) 1.87 [1.71–2.03] 1.93 [1.79–2.07] 2.17 [2.04–2.31]
 Male (N = 90) 1.35 [1.11–1.59] 1.68 [1.46–1.90] 1.90 [1.67–2.12]
 p value  < .001 ns  < .05
MacNew—global
 Top tertile (N = 43) 2.50 [2.32–2.69] 2.40 [2.13–2.66] 2.77 [2.68–2.86]
 Bottom tertile (N = 26) 1.17 [1.01–1.33] 1.06 [0.87–1.26] 1.44 [1.24–1.63]
 p value  < .001  < .001  < .001
HADS*
 Anxious (N = 35) 1.12 [0.93–1.31] 1.38 [1.13–1.62] 1.20 [0.96–1.43]
 Not anxious (N = 87) 1.98 [1.83–2.14] 2.03 [1.91–2.15] 2.41 [2.32–2.49]
 p value  < .001  < .001  < .001
 Depressed (N = 39) 1.13 [0.93–1.33] 1.33 [1.13–1.53] 1.40 [1.18–1.61]
 Not depressed (N = 81) 2.03 [1.88–2.18] 2.10 [1.98–2.23] 2.41 [2.31–2.51]
 p value  < .001  < .001  < .001
 Stressed (N = 57) 1.24 [1.07–1.41] 1.44 [1.27–1.62] 1.48 [1.31–1.65]
 Not stressed (N = 65) 2.17 [2.02–2.32] 2.18 [2.05–2.31] 2.57 [2.48–2.65]
 p value  < .001  < .001  < .001

N Number of patients

Young, < 60 years; Middle-age, 60–70 years; Elderly, > 70 years

#Middle-age versus elderly

Mean (95% confidence interval) comparisons with ANCOVAs (scores adjusted for age, sex, risk factors, and disease severity within diagnosis) and post hoc Bonferroni correction;

*HADS Hospital Anxiety and Depression Scale with cut-off score ≥ 8 for the anxiety/depression subscales and ≥ 12 for the general distress factor

Diagnosis (Table 2): Patients with MI reported significantly higher HeartQoL global scale and both physical and emotional subscale scores than patients with either AP or IHF.

MacNew (Table 6): Patients reporting higher MacNew global HRQL scores (top 33% of actual scores reported significantly higher HeartQoL global and both physical and emotional subscale scores than patients reporting lower MacNew global HRQL scores (bottom 33% of actual scores).

HADS anxiety (Table 6): Significantly higher HeartQoL global scale and both physical and emotional subscale scores were observed in patients who were not anxious than in patients who were anxious;

HADS depression (Table 6): Patients who were not depressed reported significantly higher HeartQoL global scale and both physical and emotional subscale scores than reported by patients who were depressed (p < 0.001);

HADS distress (Table 6): Significantly higher HeartQoL global scale, physical, and emotional subscale scores were observed in patients who were not distressed than in patients who were distressed;

Sex (Table 6): In the total group, female patients reported significantly higher HeartQoL global scale and both physical and emotional subscale scores than male patients; HeartQoL global scale and emotional subscale scores were significantly higher in females than males in patients with AP and in patients with IHF; in patients with MI, HeartQoL global scale and physical subscale scores were significantly higher in females than males.

Age (Table 6): The only significant HeartQoL score difference by age was a higher physical HeartQoL subscale score in middle-aged patients compared to elderly patients in the total group.

Discussion

The Italian-language version of the 14-item HeartQoL questionnaire demonstrated adequate internal consistency, convergent, divergent and discriminative validity and therefore may be recommended for the use in clinical practice and research to assess and compare HRQL in Italian-speaking IHD patients with AP, MI or IHF. The psychometric properties of the Italian version of the HeartQoL were evaluated on a sample of 472 patients with either AP, MI or IHF from five Italian centres in North-East, North-West, Central, and Southern Italy and therefore largely representative of the demographic, social, cultural, and economic characteristics of the Italian population. Further, these psychometric properties are consistent with the original validation study in patients with AP, MI or IHF, [13] the English HeartQoL version based on patients with AP or MI in the USA, [30] the German HeartQoL version in patients with AP, MI or IHF, [14] The Iranian HeartQoL version in patients with MI, [31] the EuroAspire IV study in chronic coronary syndrome patients [32] and also with validation studies in patients with atrial fibrillation, [16] implantable cardioverter defibrillator recipients [17] or following valve surgery [18]. In addition, the original two-factor structure [12], determined with Mokken scale analysis [27], was confirmed with strong physical (Hi 0.67) and emotional (Hi 0.68) domains being comparable with the original [13] and more recent validation studies. [14, 16, 17, 30, 32].

With higher HRQL scores (range 0–3) indicating better HRQL, the mean HRQL scores in the Italian HeartQoL total group were 2.0 ± 0.07 on the global scale, 1.9 ± 0.08 on the physical subscale and 2.1 ± 0.08 on the emotional subscale and all scores reported by patients with MI indicated significantly better HRQL than reported by patients with either AP or IHF. With moderate floor and ceiling effects present when > 15% patients report the lowest score (= 0; floor) or the highest score (= 3; ceiling), [26] floor and ceiling effects on the global scale and physical subscale in the total group and each diagnosis were minimal indicating detection of both deterioration and improvement. However, with the emotional subscale, although all floor effects and ceiling effects in patients with AP or IHF were minimal, the ceiling effects were moderate in the total group and in patients with MI indicating limited detection of improvement. As this outcome is consistent with the original HeartQoL study [13] and other validation studies [14, 1618, 30, 32] assessing improvement in HeartQoL emotional HRQL may be more challenging than either global or physical HRQL.

The Italian HeartQoL demonstrated high internal consistency reliability for each subscale, exceeding the recommended criterion of 0.70 for group HRQL comparisons with Cronbach’s α ≥ 0.92 on both the global scale and physical subscale and ≥ 0.84 on the emotional subscale in the total group and each of the three diagnoses. This is consistent with the previous validation studies [14, 16, 17, 30, 32] indicating that the items captured in the HeartQoL reflect the same constructs. Convergent validity refers to how closely scales measuring similar constructs are correlated, and was demonstrated across diagnostic groups with strong correlations (r > 0.70) between the physical and emotional subscales of HeartQoL and corresponding subscales of MacNew; with significantly lower correlations between dissimilar constructs, divergent validity was also confirmed.

Discriminative validity was determined using the ‘known groups’ approach [26] with the expectation that HRQL scores would distinguish between pre-identified groups. Of the total of 84 discriminative validity calculations in the total cohort and each diagnosis, 70 (83%) were fully confirmed; of the 14 calculations that were not significant, 11 (79%) were on the age and 3 (21%) on the sex variables. The discriminative validity of the Italian HeartQoL was fully confirmed for diagnosis as patients with MI reported significantly higher HeartQoL scores than patients with either AP or IHF which is largely consistent with both the original validation study [13] and the German validation study [14] as well as in the English HeartQoL where patients with MI reported higher HRQL scores than did patients with AP. [30] Discriminative validity was also fully confirmed with HADS anxiety/depression scales in the total group and in each diagnosis which is consistent for HADS anxiety and depression in the original study [13] and previously published HeartQoL studies. [14, 1618, 30, 32] As reported in the German HeartQoL validation publication [14] the Italian HeartQoL HRQL scores were significantly higher in patients not reporting HADS distress compared to those reporting distress. Discriminative validity was largely confirmed for sex in this study with females reporting significantly better HRQL than males but this is not consistent with the EuroAspire IV study in chronic coronary syndrome patients [32], the German HeartQoL observations in patients with AP, MI or IHF [14] or the studies in Danish patients with atrial fibrillation [16] or following valve surgery [18] where males reported higher HRQL, although not always significant, than females. Finally, except for significantly higher physical HeartQoL scores in middle-aged patients than in elderly patients, discriminative validity was not confirmed for age in the present study. There was a trend for lower HRQL to be reported by elderly Italian patients which is largely consistent with the EuroAspire IV study [32] but not with the German HeartQoL observations [14] where the hypothesized lower HRQL scores in older patients was not consistently met.

Limitations and strengths of the study

In every questionnaire with a relatively small number of items per scale, the amplitude of assessment of differences or changes in HRQL may be limited. Furthermore, examination of test–retest reproducibility was not possible with the cross-sectional design of the study which is also the major limitation of the present validation study not allowing for the determination of responsiveness. Future studies will be needed to determine the evaluative validity of the Italian HeartQoL questionnaire. The strength of the study lies in the demonstration of adequate key psychometric attributes of internal consistency reliability and convergent, divergent, and discriminative validity in Italian-speaking patients with ischemic heart disease.

Conclusion

The Italian version of the HeartQoL questionnaire demonstrated satisfactory psychometric characteristics showing excellent internal consistency reliability and adequate convergent, divergent, and discriminative validity in Italian speaking patients with IHD and its three major diagnoses (AP, MI, and IHF). The Italian HeartQoL can be recommended to clinicians and researchers to estimate and compare the impact of IHD on patients’ HRQL.

Acknowledgements

Link to access the Italian HeartQoL: https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/HeartQoL.

Abbreviations

AP

Angina pectoris

HRQL

Health-related quality of life

IHD

Ischemic heart disease

IHF

Ischemic heart failure

MI

Myocardial infarction

Author contributions

N.O. and F.F. designed the study. S.H. performed the data analysis. M.E.A., G.B., F.G., D.M., C.V., L.P., F.T collected the data. A.A wrote the manuscript with the support of F.F. and N.O. N.M supervised the project and revised the manuscript. All authors provided critical feedback and approved the manuscript for publication.

Funding

Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement.

Declarations

Conflict of interest

The authors declare that they have no conflict of interest or any competing interests.

Ethics approval

This study was approved by either the respective ethics committees or Institutional Review Boards.

Informed consent

Written informed consent was obtained from all individual participants included in the study.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Crossing the Quality Chasm: A New Health System for the 21st Century. National Academies Press; 2001:10027. doi:10.17226/10027 [PubMed]
  • 2.Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi: 10.1093/eurheartj/ehz425. [DOI] [PubMed] [Google Scholar]
  • 3.CDER Patient-Focused Drug Development | FDA. Accessed February 4, 2021. https://www.fda.gov/drugs/development-approval-process-drugs/cder-patient-focused-drug-development
  • 4.Anker SD, Agewall S, Borggrefe M, et al. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. Eur Heart J. 2014;35(30):2001–2009. doi: 10.1093/eurheartj/ehu205. [DOI] [PubMed] [Google Scholar]
  • 5.Rumsfeld JS, Alexander KP, Goff DC, et al. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the american heart association. Circulation. 2013;127(22):2233–2249. doi: 10.1161/CIR.0b013e3182949a2e. [DOI] [PubMed] [Google Scholar]
  • 6.Deshpande P, Sudeepthi Bl, Rajan S, Abdul Nazir C. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011;2(4):137. doi:10.4103/2229-3485.86879 [DOI] [PMC free article] [PubMed]
  • 7.Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51(11):903–912. doi: 10.1016/S0895-4356(98)00081-X. [DOI] [PubMed] [Google Scholar]
  • 8.Ware JE, Kosinski M. SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1. QualityMetric; 2005.
  • 9.Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25(2):333–341. doi: 10.1016/0735-1097(94)00397-9. [DOI] [PubMed] [Google Scholar]
  • 10.Rector TS, Kubo SH, Cohn JN. Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71(12):1106–1107. doi: 10.1016/0002-9149(93)90582-W. [DOI] [PubMed] [Google Scholar]
  • 11.Höfer S, Lim L, Guyatt G, Oldridge N. The MacNew heart disease health-related quality of life instrument: a summary. Health Qual Life Outcomes. 2004;2(1):3. doi: 10.1186/1477-7525-2-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Oldridge N, Höfer S, McGee H, et al. The HeartQoL: Part I. Development of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiolog. 2014;21(1):90–97. doi: 10.1177/2047487312450544. [DOI] [PubMed] [Google Scholar]
  • 13.Oldridge N, Höfer S, McGee H, et al. The HeartQoL: Part II Validation of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiolog. 2014;21(1):98–106. doi: 10.1177/2047487312450545. [DOI] [PubMed] [Google Scholar]
  • 14.Huber A, Oldridge N, Benzer W, Saner H, Höfer S. Validation of the German HeartQoL: a short health-related quality of life questionnaire for cardiac patients. Qual Life Res. 2020;29(4):1093–1105. doi: 10.1007/s11136-019-02384-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Luan L, Hu H, Oldridge N, et al. The psychometric evaluation of the Chinese version HeartQoL Questionnaire among patients with ischemic Heart disease in China. Submitted to Value in Health—Asian Region. [DOI] [PubMed]
  • 16.Kristensen MS, Zwisler A-D, Berg SK, et al. Validating the HeartQoL questionnaire in patients with atrial fibrillation. Eur J Prev Cardiolog. 2016;23(14):1496–1503. doi: 10.1177/2047487316638485. [DOI] [PubMed] [Google Scholar]
  • 17.Zangger G, Zwisler A-D, Kikkenborg Berg S, et al. Psychometric properties of HeartQoL, a core heart disease-specific health-related quality of life questionnaire, in Danish implantable cardioverter defibrillator recipients. Eur J Prev Cardiolog. 2018;25(2):142–149. doi: 10.1177/2047487317733074. [DOI] [PubMed] [Google Scholar]
  • 18.Grønset CN, Thygesen LC, Berg SK, et al. Measuring HRQoL following heart valve surgery: the HeartQoL questionnaire is a valid and reliable core heart disease instrument. Qual Life Res. 2019;28(5):1245–1253. doi: 10.1007/s11136-018-02098-1. [DOI] [PubMed] [Google Scholar]
  • 19.Lohr KN. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002;11(3):193–205. doi: 10.1023/A:1015291021312. [DOI] [PubMed] [Google Scholar]
  • 20.Campeau L. Letter: Grading of angina pectoris. Circulation. 1976;54(3):522–523. doi: 10.1161/circ.54.3.947585. [DOI] [PubMed] [Google Scholar]
  • 21.Costantini M, Musso M, Viterbori P, et al. Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. 1999;7(3):121–127. doi: 10.1007/s005200050241. [DOI] [PubMed] [Google Scholar]
  • 22.Palacios JE, Khondoker M, Achilla E, Tylee A, Hotopf M (2016) A single, one-off measure of depression and anxiety predicts future symptoms, higher healthcare costs, and lower quality of life in coronary heart disease patients: analysis from a multi-wave, primary care cohort study. Hashimoto K, ed. PLoS ONE.;11(7):e0158163. Doi:10.1371/journal.pone.0158163 [DOI] [PMC free article] [PubMed]
  • 23.Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardiol. 1991;67(13):1084–1089. doi: 10.1016/0002-9149(91)90870-Q. [DOI] [PubMed] [Google Scholar]
  • 24.Valenti L, Lim L, Heller RF, Knapp J. An improved questionnaire for assessing quality of life after acute myocardial infarction. Qual Life Res. 1996;5(1):151–161. doi: 10.1007/BF00435980. [DOI] [PubMed] [Google Scholar]
  • 25.Fattirolli F, Marchionni N, Höfer S, et al. The Italian MacNew heart disease health-related quality of life questionnaire: a validation study. Intern Emerg Med. 2015;10(3):359–368. doi: 10.1007/s11739-015-1203-y. [DOI] [PubMed] [Google Scholar]
  • 26.Terwee CB, Bot SDM, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42. doi: 10.1016/j.jclinepi.2006.03.012. [DOI] [PubMed] [Google Scholar]
  • 27.Meijer RR, Baneke JJ. Analyzing psychopathology items: a case for nonparametric item response theory nglishg. Psychol Methods. 2004;9(3):354–368. doi: 10.1037/1082-989X.9.3.354. [DOI] [PubMed] [Google Scholar]
  • 28.Taber KS. The use of cronbach’s alpha when developing and reporting research instruments in science education. Res Sci Educ. 2018;48(6):1273–1296. doi: 10.1007/s11165-016-9602-2. [DOI] [Google Scholar]
  • 29.Steiger JH. Testing pattern hypotheses on correlation matrices: alternative statistics and some empirical results. Multivar Behav Res. 1980;15(3):335–352. doi: 10.1207/s15327906mbr1503_7. [DOI] [PubMed] [Google Scholar]
  • 30.Oldridge N, Cho C, Thomas R, Low M, Höfer S. Validation of the nglish version of the heartqol health-related quality of life questionnaire in patients with coronary heart disease. J Cardiopulm Rehabil Prev. 2018;38(2):92–99. doi: 10.1097/HCR.0000000000000248. [DOI] [PubMed] [Google Scholar]
  • 31.Ranjandish F, Mahmoodi H, Shaghaghi A. Psychometric responsiveness of the health-related quality of life questionnaire (HeartQoL-P) in the Iranian post-myocardial infarction patients. Health Qual Life Outcomes. 2019;17(1):10. doi: 10.1186/s12955-018-1075-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.De Smedt D, Clays E, Höfer S, et al. Validity and reliability of the HeartQoL questionnaire in a large sample of stable coronary patients: the EUROASPIRE IV study of the European society of cardiology. Eur J Prev Cardiolog. 2016;23(7):714–721. doi: 10.1177/2047487315604837. [DOI] [PubMed] [Google Scholar]

Articles from Internal and Emergency Medicine are provided here courtesy of Springer

RESOURCES